News

Minutes of Implanet’s Annual General Meeting Held on June 9, 2022

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical…

2 years ago

Scientific Industries Integrates Important New Features into its VIVID Pill Counting Solution to Deliver Digitally Simplified Pharmacy Automation

BOHEMIA, NY / ACCESSWIRE / June 10, 2022 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a…

2 years ago

Jaguar Health to Participate in BIO International Convention (BIO 2022)

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea…

2 years ago

IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022

MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported…

2 years ago

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing…

2 years ago

Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…

2 years ago

ABVC BioPharma Announces Termination of Two Contracts

FREMONT, CA, June 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…

2 years ago

ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

81% of evaluable patients achieved an objective responseDeep responses: 64% are CR/CRi, of which 86% achieved transfusion independenceRapid and durable…

2 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE…

2 years ago

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for…

2 years ago